Optovue Announces New AngioVue Retina Imaging System Commercial Availability

FREMONT, Calif.–(BUSINESS WIRE)–Optovue,
the global leader in the development of optical coherence tomography (OCT)
and OCT angiography (OCTA),
today announced immediate availability of AngioVue™
Retina, a proprietary imaging system that provides retina
specialists with a non-invasive, dyeless way to quickly visualize blood
flow in the retina, the light sensitive portion in the back of the eye.
AngioVue Retina is configured with essential OCTA and OCT features
designed specifically for retinal practices to allow adoption of OCT and
OCTA into the clinical workflow with minimal disruption.
“By adding AngioVue Retina to our product portfolio, we are able to help
retinal physicians acquire OCTA technology in a cost-efficient manner
thereby adding this technology to their armamentarium of diagnostic
imaging tools,” said John
Hawley, senior vice president of Global Sales for Optovue. “OCTA
imaging is in its nascent phase and we expect applications to rapidly
unfold over the next few years. As such, we are pleased to offer this
important technology in different product configurations that meet the
needs of all ophthalmology practices.”
Optovue’s AngioVue
Retina provides retinal specialists with the ability to quickly
visualize the presence or absence of retinal vessels and assess new
information about the microvasculature with extraordinary detail. This
information may be integrated with other diagnostic imaging results to
form a complete picture of a patient’s disease state and their treatment
options.
The company also announced its new DualTrac Motion Correction for use
with both the AngioVue and AngioVue Retina systems, a two-level approach
to correcting motion artifacts resulting from patient movement. The
first level provides real-time correction for rapid eye movements,
blinking or eye drifting. The second level occurs during imaging
post-processing and corrects smaller levels of motion distortion. This
combined approach results in robust motion correction for patients who
have trouble directing their focus on a central point during an eye
exam, which is essential for high quality OCTA imaging.
Optovue recently received FDA clearance for its AngioVue
Imaging System, bringing the significant benefits of non-invasive
retinal imaging to patients
in the U.S. who suffer from diseases that lead to progressive blindness.
In addition to retina applications, the AngioVue System is a
comprehensive platform that addresses other ophthalmology applications
such as imaging the front of the eye and the optic nerve. The AngioVue
System first received regulatory clearance for use outside the US in
2014.
About OCTA
Optovue
is the first company to develop and commercialize the pioneering OCTA
technology. Utilizing light rays to form detailed three-dimensional
images of the retina, physicians are able to quickly visualize the blood
vessels. In less than three seconds, the AngioVue System acquires a
single image that complements the current angiography imaging standard,
fluorescein angiography (FA), but with a number of advantages. Unlike
FA, the AngioVue System does not require the use of dye injections,
which can often obscure the target anatomy and can lead to side effects
and other complications associated with dye-based, invasive procedures.
About Optovue
Optovue,
Inc. is a privately held medical device company founded in 2003.
Headquartered in Fremont, Calif., the company is dedicated to the
advancement and commercialization of high-speed OCT and OCTA technology
used to facilitate the diagnosis and management of eye diseases, many of
which may lead to permanent blindness. To date, there are over 100
peer-reviewed publications detailing the AngioVue Imaging System
technology and clinical applications. Optovue has installed over 10,000
products worldwide and employs over 170 people. For more information,
visit www.optovue.com.